Charles River Laboratories International, Inc. (NYSE:CRL) Shares Bought by New York State Common Retirement Fund

New York State Common Retirement Fund lifted its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 16.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 131,820 shares of the medical research company's stock after buying an additional 18,894 shares during the quarter. New York State Common Retirement Fund owned about 0.27% of Charles River Laboratories International worth $19,842,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. D1 Capital Partners L.P. purchased a new stake in shares of Charles River Laboratories International in the fourth quarter worth $172,752,000. Assenagon Asset Management S.A. boosted its stake in Charles River Laboratories International by 1,721.1% during the 1st quarter. Assenagon Asset Management S.A. now owns 570,097 shares of the medical research company's stock valued at $85,811,000 after purchasing an additional 538,792 shares during the last quarter. Norges Bank purchased a new stake in shares of Charles River Laboratories International during the 4th quarter valued at about $98,886,000. Wellington Management Group LLP boosted its holdings in Charles River Laboratories International by 9.0% in the fourth quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company's stock worth $752,508,000 after purchasing an additional 335,658 shares during the last quarter. Finally, Nomura Holdings Inc. purchased a new position in shares of Charles River Laboratories International in the 4th quarter worth $56,820,000. Hedge funds and other institutional investors own 98.91% of the company's stock.

Insider Buying and Selling

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of the company's stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total value of $72,705.00. Following the transaction, the executive vice president owned 19,513 shares of the company's stock, valued at $2,837,385.33. This represents a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 1.30% of the company's stock.

Charles River Laboratories International Stock Performance

Shares of NYSE:CRL traded down $2.15 during midday trading on Friday, reaching $154.55. The company's stock had a trading volume of 493,642 shares, compared to its average volume of 1,035,730. The firm has a market capitalization of $7.59 billion, a PE ratio of -237.77, a P/E/G ratio of 5.31 and a beta of 1.49. Charles River Laboratories International, Inc. has a twelve month low of $91.86 and a twelve month high of $254.15. The stock has a fifty day moving average of $147.42 and a 200 day moving average of $150.81. The company has a quick ratio of 1.16, a current ratio of 1.43 and a debt-to-equity ratio of 0.78.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, topping analysts' consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a negative net margin of 0.66% and a positive return on equity of 15.19%. The business had revenue of $984.17 million for the quarter, compared to analysts' expectations of $942.34 million. During the same quarter last year, the company earned $2.27 EPS. The business's revenue was down 2.7% on a year-over-year basis. On average, equities analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Barclays lifted their price objective on Charles River Laboratories International from $145.00 to $155.00 and gave the company an "equal weight" rating in a research report on Thursday, May 8th. Robert W. Baird boosted their price target on Charles River Laboratories International from $118.00 to $140.00 and gave the stock a "neutral" rating in a report on Thursday, May 8th. Cowen raised Charles River Laboratories International from a "hold" rating to a "buy" rating in a report on Wednesday, May 14th. The Goldman Sachs Group cut shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and decreased their price target for the stock from $190.00 to $170.00 in a research note on Friday, March 21st. Finally, Evercore ISI upped their price objective on Charles River Laboratories International from $170.00 to $180.00 and gave the stock an "outperform" rating in a report on Wednesday, July 9th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Charles River Laboratories International has a consensus rating of "Hold" and a consensus price target of $174.54.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).